Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Launched by ACADEMISCH ZIEKENHUIS MAASTRICHT · Jul 2, 2018
Trial Information
Current as of May 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Southeast Netherlands Advanced Metastatic Breast Cancer Registry, also known as the SONABRE Registry, is a study that aims to gather detailed information about patients diagnosed with advanced or metastatic breast cancer in the Netherlands since 2007. This study is being conducted across 11 hospitals, and it seeks to understand various aspects of the disease, including patient health, characteristics of tumors, and treatments received. By collecting data from electronic medical records, researchers hope to better understand how advanced breast cancer affects patients and how different treatments work in real-life settings.
To be eligible for this study, patients must have been diagnosed with advanced breast cancer—either as a new diagnosis or a recurrence—since 2007 and have received treatment at one of the participating hospitals. There are no exclusions based on age or gender, meaning everyone diagnosed with advanced breast cancer at these hospitals can potentially participate. Participants can expect that their medical information will be reviewed and used to help improve care for others facing similar challenges. It's also important to note that the study will continue to enroll patients until at least 2025, with the possibility of extending further.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with de novo or recurrent advanced breast cancer since 2007
- • Diagnosed with or treated for advanced breast cancer in one of the participating hospitals
- • Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard/Heerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven/Eindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo/Venray (2013-2025), all in the Netherlands.
- • Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible.
- • The inclusion period may be prolonged after 2025.
- • Exclusion Criteria: none
About Academisch Ziekenhuis Maastricht
Academisch Ziekenhuis Maastricht (AZM) is a leading academic medical center located in Maastricht, Netherlands, dedicated to advancing healthcare through innovative research and patient-centered care. As a prominent institution in the field of clinical trials, AZM integrates cutting-edge scientific research with clinical practice, fostering collaborations across disciplines to enhance therapeutic options and improve patient outcomes. With a commitment to high ethical standards and regulatory compliance, AZM actively engages in a diverse range of clinical studies, contributing to the global body of medical knowledge while ensuring the highest quality of care for its patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials